Comparative Pharmacology
Head-to-head clinical analysis: ATIVAN versus PRAZEPAM.
Head-to-head clinical analysis: ATIVAN versus PRAZEPAM.
ATIVAN vs PRAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Prazepam is a benzodiazepine that potentiates gamma-aminobutyric acid (GABA) activity at GABA-A receptors, leading to increased chloride ion influx, neuronal hyperpolarization, and central nervous system depression.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
10-30 mg orally 3-4 times daily; maximum daily dose 60 mg.
None Documented
None Documented
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Clinical Note
moderatePrazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone propionate."
Clinical Note
moderatePrazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Prazepam."
Clinical Note
moderatePrazepam + Cyclosporine
Terminal elimination half-life: 36-200 hours (mean ~75 hours). Long half-life leads to accumulation with repeated dosing and prolonged sedation, especially in elderly or hepatic impairment.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Primarily renal (as conjugated metabolites, mainly oxazepam glucuronide): ~95%; fecal: ~5%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Prazepam."